EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives

Désirée Sexauer iD, Elin S Gray, Helen Rizos, Pauline Zaenker, Aaron B Beasley iD

Neuro-Oncology Advances · 12.01.2026 · 8 (1)

DOI: 10.1093/noajnl/vdag142 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology Advances, online erschienen am 26.06.2026. Verfasst von Désirée Sexauer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.). Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Australian Government Research Training Program (RTP) Stipend Scholarship and a Melanoma Institute Australia Postgraduate Research Top-up Scholarship, Medical Research Future Fund grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parenchymal brain metastases of solid malignancies remain a significant clinical challenge, as they are often detected at later symptomatic stages, which are typically associated with worse prognosis. Delayed detection limits treatment options and contributes to poor outcomes, while early detection is critical for improving patient outcomes and quality of life. In this comprehensive review, we investigated the potential use and challenges of blood-based biomarkers, including circulating tumor cells, cell-free DNA, noncoding RNAs, extracellular vesicles, proteins, and other immune-related biomarkers, for the early detection of parenchymal brain metastasis. The use of blood-based liquid biopsies offers a promising avenue for early detection and monitoring of brain metastases, potentially enabling timely intervention and tailored treatment regimes. Continued research and rigorous clinical validation are essential to fully harness the potential of blood-based biomarkers, which could transform clinical practice in oncology.

Schlagwörter

Stichwörter der Autor:innen

biomarkersdiagnosisintracranial metastasisliquid biopsyparenchymal brain metastasis

Autor:innen und Institutionen

  • Centre for Precision Health, Edith Cowan University, Perth, WA, Australia (D.S., E.S.G., P.Z., A.B.B.).
  • School of Medical and Health Sciences, Edith Cowan University, Perth, WA, Australia.
  • Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia.
  • Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia (H.R.).

ORCID-Profile: Désirée Sexauer, Aaron B Beasley

Förderung

  • Australian Government Research Training Program (RTP) Stipend Scholarship and a Melanoma Institute Australia Postgraduate Research Top-up Scholarship
  • Medical Research Future Fund grant

Zitieren

APA

Sexauer, D., Gray, E. S., Rizos, H., Zaenker, P., & Beasley, A. B. (2026). Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives. Neuro-Oncology Advances, 8(1). https://doi.org/10.1093/noajnl/vdag142

Vancouver

Sexauer D, Gray ES, Rizos H, Zaenker P, Beasley AB. Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives. Neuro-Oncology Advances. 2026;8(1). doi:10.1093/noajnl/vdag142

BibTeX
@article{Sexauer2026,
  author = {Sexauer, Désirée and Gray, Elin S and Rizos, Helen and Zaenker, Pauline and Beasley, Aaron B},
  title = {Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives},
  journal = {Neuro-Oncology Advances},
  year = {2026},
  volume = {8},
  number = {1},
  doi = {10.1093/noajnl/vdag142}
}
Kostenlos starten →